

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
07 August 2025 (07.08.2025)



(10) International Publication Number
WO 2025/161898 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) A61P 37/06 (2006.01)
C12N 15/13 (2006.01) A61P 37/02 (2006.01)
A61K 39/395 (2006.01) A61P 37/00 (2006.01)

(21) International Application Number:

PCT/CN2025/071507

(22) International Filing Date:

09 January 2025 (09.01.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2024/075517
02 February 2024 (02.02.2024) CN
PCT/CN2024/092997
14 May 2024 (14.05.2024) CN
PCT/CN2024/110179
06 August 2024 (06.08.2024) CN

(71) Applicant: **BIOCYTOGEN PHARMACEUTICALS
(BEIJING) CO., LTD.** [CN/CN]; No.12, Baoshen South

Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing 102600 (CN).

(72) Inventors: **AN, Wenqian**; No.12, Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing 102600 (CN). **WANG, Zilin**; No.12, Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing 102600 (CN). **LIU, Baihong**; No.12, Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing 102600 (CN). **LIU, Qiang**; No.12, Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing 102600 (CN). **ZHU, Tao**; No.12, Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing 102600 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: ANTI-OX40 ANTIBODIES AND USES THEREOF




FIG. 7C

(57) Abstract: Provided are anti-OX40 antibodies or antigen binding fragments, and antigen-binding protein constructs (e.g. bispecific antibodies or antigen-binding fragments thereof), wherein the antigen-binding protein constructs specifically bind to two distinct antigenic epitopes on OX40.

[Continued on next page]

WO 2025/161898 A1

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN,
WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))